Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pluvicto renal impairment dosimetry and safety study in progressive PSMA-positive mCRPC
2023-503925-20-00Phase 2Authorised
- Sponsor
- Novartis
- Start
- Apr 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label trial of lutetium lu 177 vipivotide tetraxetan in prostate cancer (PCa) (3 cohorts), sponsored by Novartis. Primary endpoints: Absorbed radiation dose in kidney and selected organs, Blood pharmacokinetics of AAA617 and 2 more. Planned start Apr 2024; status: authorised.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2023-503925-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503925-20-00.